Interactions

Displaying 401 - 600 of 1240

ARV

Drug 2

Color Code

Drug 1 dose (field_drug_1_dose)

Drug doses

ID	Title	drug 1 Sort descending	drug 1 dose	drug 1 effect	drug 2	drug 2 dose	drug 2 effect	Clinical Effects	Color	Clinical Bottom Line	Management	Alt Agents
6272	Rilpivirine SOF/VEL 657	Rilpivirine	25 mg	Rilpivirine Cmin decreased 7%	Sofosbuvir / Velpatasvir	400 mg / 100 mg			Green: Administer standard doses	Administer standard doses
6273	Rilpivirine CBZ 658	Rilpivirine			Carbamazepine				Red: Avoid combination	Contraindicated
6274	Rilpivirine Oxcarbazepine 659	Rilpivirine			Oxcarbazepine				Red: Avoid combination	Contraindicated
6259	Rilpivirine Methadone 644	Rilpivirine	25 mg daily	No significant change	Methadone	60-100 mg daily	R-methadone AUC decreased 16%; Cmin decreased 22%; S-methadone AUC decreased 16%; Cmin decreased 21%;	Potentially decreased methadone effects (eg, withdrawal)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6275	Rilpivirine St. John's Wort (Hypericum perforatum) 660	Rilpivirine			St. John's Wort				Red: Avoid combination	Contraindicated
6260	Rilpivirine Aluminum and magnesium hydroxide antacid 645	Rilpivirine			Aluminum and magnesium hydroxide antacid			Potentially decreased rilpivirine effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rilpivirine	Administer antacids either at least 2 hours before or at least 4 hours after rilpivirine.
6276	Rilpivirine RPT 661	Rilpivirine			Rifapentine				Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine
6261	Rilpivirine Famotidine 646	Rilpivirine	150 mg x 1	Rilpivirine AUC decreased 76%; Cmax decreased 85%	Famotidine	40 mg x 1 taken 2 hours before rilpivirine		Decreased rilpivirine effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rilpivirine	Administer H2-antagonist by at least 12 hours before rilpivirine or at least 4 hours after rilpivirine.
6277	Rilpivirine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 662	Rilpivirine	25 mg daily	RPV increased 155%; AUC increased 225%; Cmin increased 262%	Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir	paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg BID	Dasabuvir Cmax increased 18%; AUC increased 17%; Cmin increased 10%. Ombitasvir AUC increased 9%. Paritaprevir Cmin increased 30%, AUC increased 23%; Cmin decreased 5%.	Potential for QT interval prolongation with higher concentrations of RPV.	Red: Avoid combination	Do not coadminister: Increased levels of rilpivirine	Use alternative agents
6262	Rilpivirine Ketoconazole 647	Rilpivirine	150 mg daily	Rilvpivirine AUC increased 49%; Cmin increased 76%; Cmax increased 30%	Ketoconazole	400 mg daily	Ketoconazole AUC decreased 24%; Cmin decreased 66%; Cmax decreased 15%	Decreased ketoconazole effects	Green: Administer standard doses	Administer standard doses	Monitor for failure of antifungal therapy
6278	Rilpivirine Omeprazole 663	Rilpivirine	150 mg daily	Rilpivirine AUC decreased 40%; Cmin decreased 33%; Cmax decreased 40%	Omeprazole	20 mg daily	No significant change	Decreased rilpivirine effects	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Contraindicated. Use alternative agents.	H2-antagonists if administered at least 12 hours before rilpivirine or at least 4 hours after rilpivirine.
6375	Atazanavir Diltiazem 760	Atazanavir	400 mg daily on days 1-11	No significant change	Diltiazem	180 mg daily on days 7-11 and 19-23	Diltiazem AUC increased 125%, Cmax increased 198%, Cmin decreased 59%	Potential for increased diltiazem effects (eg, hypotension, heart block)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of diltiazem	Reduce diltiazem dose by 50%. ECG monitoring is recommended.
6391	Atazanavir Pantoprazole 776	Atazanavir			Pantoprazole				Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Administer proton pump inhibitor at least 12 hours before atazanavir / cobicistat. Proton pump inhibitors should not exceed a dose equivalent to omeprazole 20 mg daily in protease inhibitor naive patients. Proton pump inhibitors are not recommended in protease inhibitor experienced patients.
6407	Atazanavir Famotidine 792	Atazanavir	300 mg daily with ritonavir 100 mg daily on d 1-20 (simultaneous administration)	Atazanavir AUC decreased 18%, Cmax no significant change, Cmin decreased 28%	Famotidine	40 mg BID on d 11-20	Not reported	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6423	Atazanavir Dabigatran 808	Atazanavir			Dabigatran			Potential for increased risk of bleeding	Green: Administer standard doses	Administer standard doses	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
6439	Atazanavir NVP 824	Atazanavir			Nevirapine	Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	Contraindicated. Use alternative agents.
6455	Atazanavir EVG/c 840	Atazanavir	300 mg daily	Atazanavir Cmax decreased 24%, Cmin decreased 20%	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide	Elvitegravir 85 mg daily with cobicistat 150 mg daily	Elvitegravir AUC increased 17%, Cmax decreased 16%, Cmin increased 83%	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Use alternative agents
6471	Atazanavir Flecainide 856	Atazanavir			Flecainide			Potential for increased risk of flecainide adverse effects (eg, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for toxicity. Consider therapeutic drug monitoring
6376	Atazanavir Ethinyl estradiol / Norethindrone acetate 761	Atazanavir	400 mg daily x 14 days		Ethinyl estradiol / Norethindrone acetate	1 tab daily (7 / 7 / 7)	Norethindrone Cmax increased 67%, AUC increased 110%, Cmin increased 262%, Ethinyl estradiol AUC increased 48%, Cmax no significant change, Cmin increased 91%	Increased norethindrone and ethinyl estradiol effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of hormonal contraception	For unboosted atazanavir, use an oral contraceptive that contains no more than 30 mcg of ethinyl estradiol or recommend an alternative contraceptive method. Oral contraceptives containing less than 25mcg of ethinyl estradiol or progestins other than norethindrone or norgestimate have not been studied.	Non hormonal contraceptive method, barrier devices, condoms
6392	Atazanavir Esomeprazole 777	Atazanavir			Esomeprazole			Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir if boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 blockers
6408	Atazanavir Famotidine 793	Atazanavir	400 mg daily	Atazanavir AUC decreased 38%, Cmax decreased 42%, Cmin decreased 40%	Famotidine	40 mg Q12H	Not reported	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6424	Atazanavir Dabigatran 809	Atazanavir			Dabigatran			Potential for increased risk of bleeding	Green: Administer standard doses	Administer standard doses	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
6440	Atazanavir HMG-CoA Reductase Inhibitors 825	Atazanavir			Lovastatin			Increased lovastatin effects (eg, myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Contraindicated. Use alternative agents.	Atorvastatin (low dose), Pravastatin
6456	Atazanavir ETR 841	Atazanavir	400 mg daily	Atazanavir AUC decreased 17%, Cmin decreased 47%	Etravirine		Etravirine AUC increased 50%, Cmax increased 47%, Cmin increased 58%	Potential increased etravirine effects, decreased atazanavir effects	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir and increased levels of etravirine	Use alternative agents
6472	Atazanavir Lidocaine 857	Atazanavir			Lidocaine				Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor adverse effects and consider therapeutic drug monitoring.
6377	Atazanavir Itraconazole 762	Atazanavir			Itraconazole				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of itraconazole	Unless guided by therapeutic drug monitoring, limit doses of itraconazole to less than 200 mg daily when used with atazanavir / cobicistat.
6393	Atazanavir Omeprazole 778	Atazanavir	400 mg daily on d 1-12	Not reported	Omeprazole	40 mg x 1 on d 7 and 20	Omeprazole AUC increased 45%, Cmax increased 24%	Increased omeprazole effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6409	Atazanavir Famotidine 794	Atazanavir	300 mg daily with 100 mg ritonavir daily with tenofovir on d 11-17	Atazanavir AUC decreased 41%	Famotidine	20 mg BID on d 11-17		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6425	Atazanavir DTG 810	Atazanavir	300 mg daily with ritonavir 100 mg daily	Not reported	Dolutegravir	30 mg daily	Dolutegravir AUC increased 62%, Cmax increased 34%, Cmin increased 121%		Green: Administer standard doses	Administer standard doses
6441	Atazanavir Lurasidone 826	Atazanavir			Lurasidone			Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)	Red: Avoid combination	Do not coadminister: Potential for increased levels of lurasidone	Contraindicated. Use alternative agents.
6457	Atazanavir Erythromycin 842	Atazanavir			Erythromycin				Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination, use alternative antibiotics	Azithromycin
6473	Atazanavir Amiodarone 858	Atazanavir			Amiodarone			Potential for increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor for amiodarone toxicity. Consider ECG and amiodarone drug level monitoring.
6378	Atazanavir MVC 763	Atazanavir	400 mg daily	Not reported	Maraviroc	300 mg BID	Maraviroc AUC increased 257%, Cmax increased 109%, Cmin increased 319%	Potential increase in maraviroc adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Decrease maraviroc dose to 150 mg BID
6394	Atazanavir Omeprazole 779	Atazanavir	300 mg daily with 100 mg ritonavir daily on d 7-16 then 400 mg atazanavir daily with 100 mg ritonavir daily on d 17-23	Atazanavir AUC decreased 30%, Cmin decreased 31%, Cmax decreased 31%	Omeprazole	20 mg daily on d 17-23		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6410	Atazanavir Famotidine 795	Atazanavir	400 mg daily on d 1-12 (simultaneous administration)	Atazanavir AUC decreased 41%, Cmax decreased 47%, Cmin decreased 42%	Famotidine	40 mg BID on d 7-12		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6426	Atazanavir DTG 811	Atazanavir	400 mg daily	Not reported	Dolutegravir	30 mg daily	Dolutegravir AUC increased 91%, Cmax increased 50%, Cmin increased 180%		Green: Administer standard doses	Administer standard doses
6442	Atazanavir Pimozide 827	Atazanavir			Pimozide			Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Contraindicated. Use alternative agents.
6458	Atazanavir Apixaban 843	Atazanavir			Apixaban			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination, use alternative anticoagulant	Dabigatran
6474	Atazanavir Propafenone 859	Atazanavir			Propafenone			Potential for increased propafenone effects (eg, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor for toxicity.
6379	Atazanavir MVC 764	Atazanavir	300 mg daily with 100 mg ritonavir daily	Not reported	Maraviroc	300 mg BID	Maraviroc AUC increased 388%, Cmax increased 167%, Cmin increased 567%	Potential increase in maraviroc adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Decrease maraviroc dose to 150 mg BID
6395	Atazanavir Omeprazole 780	Atazanavir	300 mg QPM with 100 mg ritonavir QPM on d 7-16, 17-23	Atazanavir AUC decreased 42%, Cmax decreased 39%, Cmin decreased 46%	Omeprazole	20 mg daily on d 17-23		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6411	Atazanavir Famotidine 796	Atazanavir	400 mg on d 1-6, d 7-12 (10 hr after, 2 hrs before famotidine)	Atazanavir Cmin decreased 31%	Famotidine	40 mg daily on d 7-12		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6427	Atazanavir SOF/VEL 812	Atazanavir	300 mg with ritonavir 100 mg daily	Atazanavir Cmax increased 9%, AUC increased 20%, Cmin increased 39%.	Sofosbuvir / Velpatasvir	400 mg / 100 mg	Sofosbuvir AUC increased 22%. Velpatasvir Cmax increased 55%, AUC increased 142%, Cmin increased 301%		Green: Administer standard doses	Administer standard doses
6443	Atazanavir Quetiapine 828	Atazanavir			Quetiapine			Increased quentiapine effects.	Red: Avoid combination	Do not coadminister: Potential for increased levels of quentiapine. If coadministration is necessary: reduce dose to 1 / 6 of current dose.	Contraindicated. Use alternative agents.
6459	Atazanavir Phenytoin 844	Atazanavir			Phenytoin			Potential loss of antiretroviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents	Gabapentin Lamotrigine Tiagabine Topiramate
6475	Atazanavir Quinidine 860	Atazanavir			Quinidine			Potential for increased quinidine effects (e.g. cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor for toxicity.
6380	Atazanavir Pitavastatin 765	Atazanavir	300 mg daily x 5 days	No significant change	Pitavastatin	4 mg daily	Pitavastatin AUC increased 31%, Cmax increased 60%	Potential for increased pitavastatin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of pitavastatin	Start at lowest dose and titrate to effect
6396	Atazanavir Omeprazole 781	Atazanavir	400 mg daily with ritonavir 100 mg daily x 20 d	Atazanavir AUC decreased 61%, Cmax decreased 56%, Cmin decreased 66%	Omeprazole	40 mg daily x 10 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6412	Atazanavir Famotidine 797	Atazanavir	400 mg atazanavir with 100 mg ritonavir on d 11-20	Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 14%(compared to 300 mg atazanavir with 100 mg ritonavir daily)	Famotidine	40 mg Q12H on d 11-20		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6428	Atazanavir Atenolol 813	Atazanavir	400 mg daily on days 1-11	Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 26%	Atenolol	50 mg daily on days 7-11 and 19-23	Atenolol AUC increased 25%, Cmax increased 34%, Cmin no significant change		Green: Administer standard doses	Administer standard doses
6444	Atazanavir Ranolazine 829	Atazanavir			Ranolazine			Potential increase in ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias).	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine	Contraindicated. Use alternative agents.
6460	Atazanavir Phenobarbital 845	Atazanavir			Phenobarbital			Potential loss of antiretroviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents	Gabapentin Lamotrigine Tiagabine Topiramate
6476	Atazanavir Midazolam 861	Atazanavir			Midazolam			Potential for increased midazolam effects (eg, increased sedation, confusion, respiratory depression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.	Lorazepam, Oxazepam, Temazepam, Trazodone
6381	Atazanavir RFB 766	Atazanavir	600 mg daily on days 11-20	Not reported	Rifabutin	300 mg daily on days 1-10, then 150 mg daily on days 11-20	Rifabutin AUC increased 110%, Cmax increased 118%, Cmin increased 243%, 25-O-desacetylrifabutin AUC increased 2101%, Cmax increased 720%, Cmin increased 7460%	Increased rifabutin effects (eg, uveitis)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
6397	Atazanavir Omeprazole 782	Atazanavir	300 mg with ritonavir 100 mg daily with 8 oz cola x 20 d	Atazanavir AUC decreased 70%, Cmax decreased 66%, Cmin decreased 76%	Omeprazole	40 mg daily x 10 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6413	Atazanavir Famotidine 798	Atazanavir	300 mg daily with 100 mg ritonavir	No significant change	Famotidine	20 mg BID on d 11-17 (simultaneous administration with morning atazanavir / ritonavir)			Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6429	Atazanavir Fluconazole 814	Atazanavir	300 mg daily with ritonavir 100 mg daily x 10 days	No significant change	Fluconazole	200 mg daily x 10 days	No significant change		Green: Administer standard doses	Administer standard doses
6445	Atazanavir Salmeterol 830	Atazanavir			Salmeterol			QT prolongation, palpitations, and sinus tachycardia.	Red: Avoid combination	Do not coadminister: Potential for increased levels of salmeterol	Contraindicated. Use alternative agents.
6461	Atazanavir Clarithromycin 846	Atazanavir			Clarithromycin				Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider alternative antibiotics	Azithromycin
6477	Atazanavir Fluticasone 862	Atazanavir			Fluticasone			Decreased plasma cortisol concentrations (eg, Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution with atazanavir, use with atazanavir / ritonavir is not recommended unless the potential benefit outweighs the risk	Beclomethasone
6382	Atazanavir RFB 767	Atazanavir	400 mg daily on days 1-14, 400 mg daily with ritonavir 100 mg daily on days 15-28	Atazanavir AUC increased 191%, Cmax increased 81%	Rifabutin	150 mg daily on days 15-28	Not reported	Potential increase in atazanavir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
6398	Atazanavir Omeprazole 783	Atazanavir	300 mg daily with ritonavir 100 mg daily x 20 d	Atazanavir AUC decreased 76%, Cmax decreased 72%, Cmin decreased 78%	Omeprazole	40 mg daily x 10 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6414	Atazanavir EE/NGM 799	Atazanavir	300 mg atazanavir daily with 100 mg ritonavir daily		Ethinyl estradiol / Norgestimate		Ethinyl estradiol AUC decreased 19%, Cmax decreased 16%, Cmin decreased 37% 17-deacetyl norgestimate AUC increased 85%, Cmax increased 68%, Cmin increased 102%		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of hormonal contraception	With ritonavir boosted atazanavir, use an oral contraceptive containing at least 35 mcg of ethinyl estradiol. Oral contraceptives containing progestins other than norethindrone or norgestimate have not been studied.	Non-hormonal contraceptives, barrier devices, condoms
6430	Atazanavir Ketoconazole 815	Atazanavir	400 mg daily on days 1-13	No significant change	Ketoconazole	200 mg daily on days 7-13	Not reported		Green: Administer standard doses	Administer standard doses
6446	Atazanavir Simvastatin 831	Atazanavir			Simvastatin			Potential Increased simvastatin effects (eg, myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Contraindicated. Use alternative agents.	Atorvastatin (low dose), Pravastatin
6462	Atazanavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 847	Atazanavir			Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir				Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Do not coadminister
6478	Atazanavir Voriconazole 863	Atazanavir			Voriconazole	200 mg PO Q12H	Voriconazole AUC decreased 39% when given with ritonavir 100 mg BID	Potential decreased voriconazole antifungal effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	With unboosted atazanavir no dose adjustment necessary, monitor for toxicity. Do not coadminister with boosted protease inhibitors unless benefit outweighs risks. Consider therapeutic drug monitoring.
6383	Atazanavir RFB 768	Atazanavir	400 mg daily on days 1-28	Atazanavir Cmax increased 34%	Rifabutin	150 mg daily on days 15-28	Not reported		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
6399	Atazanavir Omeprazole 784	Atazanavir	400 mg daily x 12 d	Atazanavir AUC decreased 94%, Cmax decreased 96%, Cmin decreased 95%	Omeprazole	40 mg daily x 5 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6415	Atazanavir Lamotrigine 800	Atazanavir	Atazanavir 400mg daily or Atazanavir 300 mg with Ritonavir 100 mg daily	No significant change	Lamotrigine	100 mg daily	AUC decreased 32%	Atazanavir with ritonavir may decrease lamotrigine plasma concentrations, Atazanavir without ritonavir is most likely not clinically significant	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of lamotrigine	No dose adjustment necessary if administering lamotrigine and atazanavir alone. If administering lamotrigine and atazanavir plus ritonovir, lamotrigine maintenance dose may need to be increased.
6431	Atazanavir Acetaminophen 816	Atazanavir	300 mg atazanavir daily with 100 mg ritonavir daily on d 11-20	Atazanavir Cmin increased 26%	Acetaminophen	1 gram BID on days 1-20			Green: Administer standard doses	Administer standard doses
6447	Atazanavir St. John's Wort (Hypericum perforatum) 832	Atazanavir			St. John's Wort			Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6463	Atazanavir Ticagrelor 848	Atazanavir			Ticagrelor			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
6479	Atazanavir Rivaroxaban 864	Atazanavir			Rivaroxaban			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider using alternative agents	Dabigatran
6384	Atazanavir Rosuvastatin 769	Atazanavir	300 mg atazanavir daily with ritonavir 100 mg daily		Rosuvastatin	10 mg daily	Rosuvastatin AUC increased 213%, Cmax increased 600%	Potential for increased rosuvastatin adverse effects (e.g. myopathy)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rosuvastatin	Initiate lowest dose and titrate carefully. Do not exceed 10mg rosuvastatin daily.	Pravastatin, atorvastatin
6400	Atazanavir Lansoprazole 785	Atazanavir	400 mg daily	Atazanavir AUC decreased 94%, Cmax decreased 91%, half-life: no significant change	Lansoprazole	60 mg daily x 2 doses		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6416	Atazanavir Methadone 801	Atazanavir	400 mg daily on d 2-15		Methadone	stable dose on d 1-15	Total methadone Cmax decresed 15%	Potential decreased methadone effects (withdrawl, inadequate pain control, cravings)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6432	Atazanavir Alfuzosin 817	Atazanavir			Alfuzosin				Red: Avoid combination	Do not coadminister: Increased levels of alfuzosin	Contraindicated. Use alternative agents.
6448	Atazanavir Phenobarbital 833	Atazanavir			Phenobarbital			Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6464	Atazanavir Vorapaxar 849	Atazanavir			Vorapaxar			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
6480	Atazanavir Apixaban 865	Atazanavir			Apixaban			Increased apixaban levels, Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefitsÊof using this combination	Consider using alternative agents	Dabigatran
6369	Atazanavir DRV 754	Atazanavir	300 mg daily	Atazanavir Cmin increased 52%	Darunavir	400 mg BID with ritonavir 100 mg BID	No significant change		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of antiretrovirals	If used in combination, atazanavir may be given in conjunction with darunavir / ritonavir at study doses (300mg daily plus 400 / 100 mg daily)
6385	Atazanavir Sildenafil 770	Atazanavir			Sildenafil			Potentially increased sildenafil effects (eg, hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of sildenafil. (Do not coadminister for pulmonary hypertension)	For erectile dysfunction, initiate sildenafil (Viagra) 25 mg every 48 hours and monitor for adverse effects. Do not coadminister if using sildenafil for pulmonary arterial hypertension.
6401	Atazanavir Pantoprazole 786	Atazanavir			Pantoprazole			Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6417	Atazanavir LDV/SOF 802	Atazanavir	Atazanavir / ritonavir 300 mg / 100mg daily given simultaenously for 10 days plus emtricitabine / tenofovir DF 200mg / 300mg daily	Atazanavir AUC(tau) increased 43%	Ledipasvir / Sofosbuvir	90 / 400 mg	Ledipasvir AUC(tau) increased 134%, Cmax increased 75%	Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir.	Green: Administer standard doses	Administer standard doses	If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen.
6433	Atazanavir Irinotecan 818	Atazanavir			Irinotecan				Red: Avoid combination	Do not coadminister: Increased levels of irinotecan	Contraindicated. Use alternative agents.
6449	Atazanavir Phenytoin 834	Atazanavir			Phenytoin			Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6465	Atazanavir Telithromycin 850	Atazanavir			Telithromycin			Potential for increased telithromycin effects. (e.g. may cause QTc prolongation)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Avoid combination or use alternative agents
6370	Atazanavir RTV 755	Atazanavir	300 mg daily on days 1-20	Atazanavir AUC increased 238%; Cmax increased 86%; Cmin increased 1089%	Ritonavir	100 mg daily on days 11-20	Not studied	Increased atazanavir effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atazanavir	Dose atazanavir 300 mg once daily with ritonavir 100 mg daily
6386	Atazanavir Tadalafil 771	Atazanavir			Tadalafil			Potentially increased tadalafill effects (eg, hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased tadalafil levels	For erectile dysfunction initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
6402	Atazanavir Rabeprazole 787	Atazanavir			Rabeprazole			Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6418	Atazanavir LDV/SOF 803	Atazanavir	Atazanavir / ritonavir 300 mg / 100mg daily given simultaenously for 10 days plus emtricitabine / tenofovir DF 200mg / 300mg daily	Atazanavir AUC increased 27%, Cmin increased 63%	Ledipasvir / Sofosbuvir	90 / 400 mg	Ledipasvir AUC(tau) increased 96%, Cmax increased 68%.	Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir.	Green: Administer standard doses	Administer standard doses	If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen.
6434	Atazanavir SOF/VEL/VOX 819	Atazanavir			Sofosbuvir / Velpatasvir / Voxilaprevir				Red: Avoid combination	Do not coadminister: Increased levels of voxilaprevir	Contraindicated. Use alternative agents.
6450	Atazanavir CBZ 835	Atazanavir			Carbamazepine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6466	Atazanavir Atovaquone 851	Atazanavir	300 mg with 100 mg ritonavir daily	Not reported	Atovaquone	250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 46%, Cmax decreased 49%	Potential compromised antimalarial activity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dose adjustment not established. If coadministering monitor for anti-malarial efficacy.
6371	Atazanavir Clarithromycin 756	Atazanavir	400 mg daily on days 1-10	Atazanavir AUC increased 28%, Cmax no significant change, Cmin increased 91%	Clarithromycin	500 mg BID on days 7-11 and 18-21	Clarithromycin AUC increased 94%, Cmax increased 50%, Cmin decreased 62%, 14-hydroxyclarithromycin AUC decreased 70%, Cmax decreased 72%, Cmin increased 164%	Potential for increased clarithromycin effects. (e.g. may cause QTc prolongation).	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of clarithromycin	Reduce clarithromycin dose by 50%	Azithromycin
6387	Atazanavir Aluminum and magnesium hydroxide antacid 772	Atazanavir			Aluminum and magnesium hydroxide antacid				Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Separate administration of atazanavir / cobicistat and antacids by a minimum of 2 hours.
6403	Atazanavir EFV 788	Atazanavir	400 mg daily on days 1-6 then 300 mg with ritonavir 100 mg daily on days 7-20	Atazanavir (all values compared to atazanavir 400 mg daily) AUC increased 39% , Cmax no significant change, Cmin increased 48%	Efavirenz	600 mg daily x days 7-20	Not reported	Potential for increased atazanavir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6419	Atazanavir Posaconazole 804	Atazanavir	300 mg daily with 100 mg ritonavir daily	Atazanavir AUC increased 146%, Cmax increased 53%	Posaconazole	400 mg BID		Potential for increased atazanavir adverse effects	Green: Administer standard doses	Administer standard doses	Monitor closely for atazanavir adverse effects during coadministration
6435	Atazanavir Triazolam 820	Atazanavir			Triazolam			Potential for increased triazolam adverse effects (eg, increased sedation, confusion, respiratory depression)	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Contraindicated. Use alternative agents.	Lorazepam, Oxazepam, Temazepam, Trazodone
6451	Atazanavir RIF 836	Atazanavir	300 mg with 200 mg ritonavir daily x 10 d	Atazanavir AUC decreased 31%, Cmax decreased 40%, Cmin decreased 80%(compared to atazanavir 400 mg daily)	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6467	Atazanavir Digoxin 852	Atazanavir			Digoxin			Potential for increased risk of digoxin toxicity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering digoxin dose may need to be decreased. Monitor digoxin level and adjust digoxin dose based on clinical signs and drug levels.
6372	Atazanavir Colchicine 757	Atazanavir			Colchicine			Potential for increased colchicine effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of colchicine	For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose should not be repeated earlier than 3 days after. For gout prophylaxis, reduce colchicine dose to 0.3 mg daily if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg every other day if on 0.6 mg daily prior to PI therapy. For treatment of familial Mediterranean fever do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment.
6388	Atazanavir Bosentan 773	Atazanavir			Bosentan			Potential decreased antiviral effects of atazanavir	Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Do not coadminister bosentan with unboosted atazanavir, For patients receiving atazanavir plus ritonavir for >10 days, start bosentan at 62.5mg daily or every other day based on individual tolerability, Discontinue bosentan at least 36 hours before starting atazanavir / ritonavir. At least 10 days after starting atazanavir / ritonavir, resume bosentan at 62.5mg daily or every other day based on individual tolerability.
6404	Atazanavir EFV 789	Atazanavir	400 mg daily on days 1-28	Atazanavir AUC increased 241%, Cmax increased 124%, Cmin increased 671%, half-life: increased 79%	Efavirenz	600 mg daily with ritonavir 200 mg on days 15-28	Not reported	Potential for increased atazanavir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6420	Atazanavir Posaconazole 805	Atazanavir	300 mg daily	Atazanavir AUC increased 268%, Cmax increased 155%	Posaconazole	400 mg BID		Potential for increased atazanavir adverse effects	Green: Administer standard doses	Administer standard doses	Monitor closely for atazanavir adverse effects during coadministration
6436	Atazanavir RTV 821	Atazanavir		Not studied; Potential increased atazanavir levels)	Ritonavir			Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.)	Red: Avoid combination	Do not coadminister: Potential for increased levels of atazanavir	Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat
6452	Atazanavir RIF 837	Atazanavir	300 mg with 100 mg ritonavir daily x 10 d	Atazanavir AUC decreased 57%, Cmax decreased 56%, Cmin decreased 93%(compared to atazanavir 400 mg daily)	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6468	Atazanavir Proguanil 853	Atazanavir	300 mg with 100 mg ritonavir daily	Not reported	Proguanil	100 mg with 250 mg atovaquone x 1	Proguanil AUC decreased 41%, Cmax no significant change	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor for anti-malarial efficacy
6373	Atazanavir Daclatasvir 758	Atazanavir			Daclatasvir				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of daclatasvir	Decrease daclatasvir dose to 30 mg daily
6389	Atazanavir Cimetidine 774	Atazanavir			Cimetidine			Potential loss of antiviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Unboosted atazanavir 400 mg: give atazanavir 2 hrs before or 10 hours after H2-blocker. Single doses of H2-blockers should not exceed 20 mg of famotidine (or equivalent). Additionally, if treatment naive, total daily dose of H2 blocker should not exceed 40 mg of famotidine (or equivalent). Atazanavir 300 mg boosted with ritonavir or cobicistat: Give boosted atazanavir at same time as H2 blocker or 10 hours or more after. Total doses of H2 blocker should not exceed the equivalent of 40 mg BID famotidine (treatment naive) or 20 mg BID for (treatment experienced patients). If using tenofovir disoproxil fumarate, atazanavir, and H2 blocker in treatment experienced patient, increase atazanavir dose to 400 mg in addition to boosting with ritonavir or cobicistat.
6405	Atazanavir EFV 790	Atazanavir	400 mg daily on days 1-20	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%, half-life: decreased 27%	Efavirenz	600 mg daily on days 7-20	No significant change	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6421	Atazanavir Rosiglitazone 806	Atazanavir	300 mg daily with 100 mg ritonavir daily		Rosiglitazone	4 mg x 1	Rosiglitazone AUC decreased 17%	Potential decreased glycemic control	Green: Administer standard doses	Administer standard doses	Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir
6437	Atazanavir Ergotamine 822	Atazanavir			Ergotamine			Potential for increased ergotamine effects (eg, ergotism)	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Contraindicated. Use alternative agents.	5-HT agonists ("triptans")
6453	Atazanavir RIF 838	Atazanavir	300 mg with 100 mg ritonavir daily x 21 d	Atazanavir AUC decreased 72%, Cmax decreased 53%, Cmin decreased 98%	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6469	Atazanavir Disopyramide 854	Atazanavir			Disopyramide			Potential for increased risk of disopyramide adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for disopyramide toxicity
6374	Atazanavir Daclatasvir 759	Atazanavir	300 mg with ritonavir 100 mg daily	No significant change	Daclatasvir	20 mg daily	AUC(tau) increased 110%		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of daclatasvir	Decrease daclatasvir dose to 30 mg daily when used with atazanavir / ritonavir. No dose adjustment necessary if used with unboosted atazanavir.
6390	Atazanavir TDF 775	Atazanavir	300 mg daily with ritonavir 100 mg daily on days 1-42	Atazanavir Cmax decreased 28%, AUC decreased 25%, Cmin decreased 26%, Ritonavir Cmax decreased 28%, AUC decreased 25%, Cmin no significant change	Tenofovir Disoproxil Fumarate	300 mg daily on days 15-42	Not reported	Potential loss of antiretroviral efficacy with lower atazanavir concentrationss. Potential for increased tenofovir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. Do not coadminister TDF with unboosted atazanavir (400 mg).
6406	Atazanavir EFV 791	Atazanavir	600 mg daily on days 7-20	Atazanavir (all values compared to atazanavir 400 mg daily) AUC decreased 21%, Cmax no significant change, Cmin decreased 59%	Efavirenz	600 mg daily on days 7-20	Not reported	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6422	Atazanavir Rosiglitazone 807	Atazanavir	400 mg daily		Rosiglitazone	4 mg x 1	Rosiglitazone AUC increased 35%	Potential for increased rosiglitazone adverse effects	Green: Administer standard doses	Administer standard doses	Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir
6438	Atazanavir EBR/GZR 823	Atazanavir	300 mg daily with ritonavir 100 mg daily	ATV AUC increased 43% by grazoprevir	Elbasvir / Grazoprevir	Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	Contraindicated. Use alternative agents.
6454	Atazanavir RIF 839	Atazanavir	400 mg with 200 mg ritonavir daily x 10 d	Atazanavir AUC no significant change, Cmax decreased 18%, Cmin decreased 40%(compared to atazanavir 400 mg daily)	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6470	Atazanavir Mexiletine 855	Atazanavir			Mexiletine			Potential for increased risk of mexiletine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for mexiletine toxicity
6487	Darunavir Calcifediol 872	Darunavir			Calcifediol			Potential for increased risk of calcifediol adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of calcifediol	If coadministering, dose adjustment may be required. Monitor serum 25-hydroxyvitamin D, intact PTH, and serum calcium concentrations
6503	Darunavir Rosuvastatin 888	Darunavir	600 mg with 100 mg ritonavir BID	No significant change	Rosuvastatin	10 mg once daily	Cmax increase 144%,AUC increase 48%	Increased risk of rosuvastatin adverse effects (e.g. myopathy, rhabdomyolysis); No change in lipid lowering ability within 35 day study period	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rosuvastatin	Consider using alternative agents. If coadministering, consider initiating low dose rosuvastatin 5 mg daily
6519	Darunavir RPV 904	Darunavir	800 mg with 100 mg ritonavir once daily	No significant change	Rilpivirine	150 mg once daily	Cmax decrease 21%, AUC increase 130%, Cmin increase 178%	Potential for increased rilpivirine adverse effects	Green: Administer standard doses	Administer standard doses
6535	Darunavir EBR/GZR 920	Darunavir	800 mg once daily	No significant change	Elbasvir / Grazoprevir	50 / 100 mg once daily	Elbasvir AUC increase 66%; Grazoprevir AUC increase 7.5 fold	Potential for increased risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	Red: Avoid combination	Do not coadminister: Increased levels of grazoprevir	Contraindicated. Use alternative agents.
6551	Darunavir Dofetilide 936	Darunavir			Dofetilide			Potential for increased risk of dofetilide adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of dofetilide	Use alternative agents
6567	Darunavir CBZ 952	Darunavir			Carbamazepine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Contraindicated. Use alternative agents.
6583	Darunavir Fluticasone 968	Darunavir			Fluticasone			Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents
6599	Darunavir Amiodarone 984	Darunavir			Amiodarone			Potential for increased risk of amiodarone adverse effects (e.g. hypotension, bradycardia, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	If coadministering use with caution. Monitor for amiodarone toxicity. Consider ECG and amiodarone drug level monitoring.
6615	Darunavir Artemether / Lumefantrine 1000	Darunavir	600 mg with 100 mg ritonavir BID	No significant change	Artemether / Lumefantrine	80 / 480 mg	AUC decrease 16%; AUC increase 175%	Clinical significance unknown	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor closely for anti- malarial efficacy and lumefantrine toxicity. Dose adjustment not established.
6631	Darunavir Nicardipine 1016	Darunavir			Nicardipine			Increased nicardipine effects (e.g. hypotension, heart block)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor and adjust nicardipine as indicated
6647	Darunavir Betrixaban 1032	Darunavir			Betrixaban			Potential for increased bleeding risk	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
6488	Darunavir Cariprazine 873	Darunavir			Cariprazine			Potential for increased risk of cariprazine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of cariprazine	If starting cariprazine in a patient on a protease inhibitor, administer cariprazine 1.5 mg on Day 1 and Day 3, with no dose given on Day 2. From Day 4 onward, administer cariprazine 1.5 mg daily. Dose may be increased to a maximum of cariprazine 3 mg daily. If starting a protease inhibitor for a patient already taking cariprazine 3-6mg, reduce dose by half. For patients taking cariprazine 4.5 mg daily, reduced cariprazine dose to 1.5 - 3 mg daily. For patients taking cariprazine 1.5 mg daily, reduce to cariprazine 1.5 mg every other day. If PI is withdrawn, cariprazine dose may need to be increased.
6504	Darunavir Sildenafil 889	Darunavir	400 mg with 100 mg ritonavir BID	Not reported	Sildenafil	25 mg x 1	Cmax decrease 38% (compared to sildenafil 100 mg x 1 without darunavir / ritonavir)	Increased risk of sildenafil adverse effects (e.g. hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of sildenafil. (Do not coadminister for pulmonary hypertension)	For erectile dysfunction, do not exceed sildenafil 25 mg every 48 hours and monitor for adverse effects. Contraindicated if using sildenafil for pulmonary arterial hypertension.
6520	Darunavir Pitavastatin 905	Darunavir	800 mg with 100 mg ritonavir once daily	No significant change	Pitavastatin	4 mg once daily	AUC decreased 26%		Green: Administer standard doses	Administer standard doses
6536	Darunavir Propafenone 921	Darunavir			Propafenone			Potential for increased risk of propafenone adverse effects	Red: Avoid combination	Do not coadminister: Increased levels of propafenone	Use alternative agents
6552	Darunavir Ergotamine 937	Darunavir			Ergotamine			Potential for increased risk of ergotamine adverse effects (e.g. peripheral vasospasm, ischemia)	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Contraindicated. Use alternative agents.	5-HT agonists ("triptans")
6568	Darunavir St. John's Wort (Hypericum perforatum) 953	Darunavir			St. John's Wort			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Contraindicated. Use alternative agents.
6584	Darunavir Budesonide 969	Darunavir			Budesonide			Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents, particularly for long term use	Beclomethasone, prednisone, prednisolone
6600	Darunavir Dasatinib 985	Darunavir			Dasatinib			Potential for increased risk of dasatinib adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	If coadministering, decrease dose or adjust dosing interval as needed
6616	Darunavir Sirolimus 1001	Darunavir		Not studied	Sirolimus		Not studied (may increase rapamycin levels)	Increased risk of sirolimus adverse effects (supratherapeutic immunosuppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, consider initiating lower immunosuppressant dose. Therapeutic drug monitoring is recommended. Consult with specialist as necessary.
6632	Darunavir Nifedipine 1017	Darunavir			Nifedipine			Increased nifedipine effects (e.g. hypotension, bradycardia)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor and adjust nifedipine as indicated
6648	Darunavir Erythromycin 1033	Darunavir			Erythromycin			Potential for increased risk of antibacterial adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents	Azithromycin
6489	Darunavir Fesoterodine 874	Darunavir			Fesoterodine			Potential for increased risk of zolpidem adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of fesoterodine	If coadministering, do not exceed fesoterodine 4 mg once daily
6505	Darunavir Tadalafil 890	Darunavir		Not studied	Tadalafil		Not studied (may increase tadalafil levels)	Increased risk of tadalafil adverse effects (e.g. hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of tadalafil	For erectile dysfunction, initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension, initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
6521	Darunavir ATV 906	Darunavir	400 mg with 100 mg ritonavir BID	No significant change	Atazanavir	300 mg once daily	Cmax decrease 11%, AUC increase 8%, Cmin increase 52%		Green: Administer standard doses	Administer standard doses
6537	Darunavir Clopidogrel 922	Darunavir			Clopidogrel			Potential for increased bleeding risk	Red: Avoid combination	Do not coadminister: Potential for decreased clopidogrel levels	Use alternative agents
6553	Darunavir Lomitapide 938	Darunavir		Not studied	Lomitapide		Not studied	Potential for increased risk of lomitapide adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of lomitapide	Contraindicated. Use alternative agents.
6569	Darunavir Phenobarbital 954	Darunavir			Phenobarbital			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Contraindicated. Use alternative agents.
6585	Darunavir Betamethasone 970	Darunavir			Betamethasone			Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents, particularly for long term use	Beclomethasone, prednisone, prednisolone
6601	Darunavir Nilotinib 986	Darunavir			Nilotinib			Potential for increased risk of nilotinib adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	If coadministering, decrease dose or adjust dosing interval as needed
6617	Darunavir Tacrolimus 1002	Darunavir		Not studied	Tacrolimus		Not studied (may increase tacrolimus levels)	Potential for increased risk of tacrolimus adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, consider initiating lower immunosuppressant dose. Therapeutic drug monitoring is recommended. Consult with specialist as necessary.
6633	Darunavir Quinidine 1018	Darunavir			Quinidine			Potential for increased risk of quinidine adverse effects (e.g. cardiac arrhythmias, exacerbation of heart failure)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor and adjust quinidine as indicated
6490	Darunavir Fluvastatin 875	Darunavir			Fluvastatin			Potential for increased risk of fluvastatin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of fluvastatin	Consider using alternative agents. If coadministering, initate lowest recommended dose and titrate while monitoring
6506	Darunavir Thioridazine 891	Darunavir			Thioridazine			Potential for increased risk of thioridazine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of thioridazine	If coadministering, dose reduction may be necessary
6522	Darunavir DTG 907	Darunavir	600 mg with 100 mg ritonavir BID	No significant change	Dolutegravir	30 mg once daily	Cmax decrease 11%, AUC decrease 22%, Cmin decrease 38%		Green: Administer standard doses	Administer standard doses
6538	Darunavir RPT 923	Darunavir			Rifapentine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for decreased darunavir levels	Use alternative agents
6554	Darunavir HMG-CoA Reductase Inhibitors 939	Darunavir		Not studied	Lovastatin		Not studied (may increase lovastatin levels)	Increased risk of lovastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Contraindicated. Use alternative agents.	Atorvastatin (low dose)
6570	Darunavir Phenytoin 955	Darunavir			Phenytoin			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Contraindicated. Use alternative agents.
6586	Darunavir Ciclesonide 971	Darunavir			Ciclesonide			Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents, particularly for long term use	Beclomethasone, prednisone, prednisolone
6602	Darunavir Tamsulosin 987	Darunavir			Tamsulosin			Potential for increased risk of tamsulosin adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	If coadministering, monitor for clinical toxicities
6618	Darunavir Amitriptyline 1003	Darunavir			Amitriptyline			Potential for increased risk of amitriptyline adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate amitriptyline at low dose. Monitor for CNS and cardiovascular effects.
6634	Darunavir Felodipine 1019	Darunavir			Felodipine			Potential for increased risk of felodipine adverse effects (e.g. hypotension, bradycardia)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor felodipine adverse effects
6491	Darunavir Iloperidone 876	Darunavir			Iloperidone			Potential for increased risk of iloperidone adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of iloperidone	If coadministering, decrease dose of iloperidone by 50%
6507	Darunavir Vardenafil 892	Darunavir			Vardenafil			Increased risk of vardenafil adverse effects (e.g. hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of vardenafil	Do not exceed 2.5 mg dose in 72 hours
6523	Darunavir ETR 908	Darunavir	600 mg with 100 mg ritonavir BID	Not reported	Etravirine	100 mg BID	Cmax decrease 32%, AUC decrease 37%, Cmin decrease 49%		Green: Administer standard doses	Administer standard doses
6539	Darunavir Avanafil 924	Darunavir			Avanafil			Potential for increased risk of avanafil adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased avanafil levels	Use alternative agents
6555	Darunavir Pimozide 940	Darunavir			Pimozide			Potential for increased risk of pimozide adverse effects (e.g. hypotension, cardiac arrhythmias)	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Contraindicated. Use alternative agents.
6571	Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 956	Darunavir	600 mg BID with ritonavir 100 mg once daily in the evening	Cmax decrease 13%, AUC decrease 20%, Cmin decrease 43%	Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir	250 mg BID + 25 / 150 / 100 mg once daily	Dasabuvir Cmax decrease 16%, AUC decrease 27%; Cmin decrease 46%; Ombitasvir Cmax decrease 24%, AUC and Cmin decrease 27%; Paritaprevir Cmax decrease 30%, AUC decrease 41%, Cmin decrease 17%	Potential decreased anti-HCV and anti-HIV efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of darunavir	Use alternative agents
6587	Darunavir Methylprednisolone 972	Darunavir			Methylprednisolone			Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents, particularly for long term use	Beclomethasone, prednisone, prednisolone
6603	Darunavir Midazolam 988	Darunavir			Midazolam			Potential for increased risk of midazolam adverse effects (e.g. increased sedation, confusion, respiratory depression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation; chronic midazolam administration (oral or intravenous) is contraindicated	Lorazepam
6619	Darunavir Doxazosin 1004	Darunavir			Doxazosin			Potential for increased risk of doxazosin adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate at lowest dose and titrate while monitoring for clinical response / adverse effects
6635	Darunavir Ethosuximide 1020	Darunavir			Ethosuximide			Potential for increased risk of ethosuximide adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for adverse effects
6492	Darunavir Aripiprazole 877	Darunavir			Aripiprazole			Potential for increased risk of aripiprazole adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of aripiprazole	Administer 25% of the usual aripiprazole dose. Titrate dose based on clinical monitoring for efficacy / adverse events.
6508	Darunavir Pimavanserin 893	Darunavir			Pimavanserin			Potential for increased risk of pimavanserin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased pimavanserin levels	If coadministering, decrease dose of pimavanserin to 10 mg once daily
6524	Darunavir EFV 909	Darunavir	300 mg with 100 mg ritonavir twice daily	Cmax decrease 15%, AUC decrease 13%, Cmin decrease 31%	Efavirenz	600 mg once daily	Cmax increase 15%, AUC increase 21%, Cmin increase 17%		Green: Administer standard doses	Administer standard doses
6540	Darunavir Bedaquiline 925	Darunavir			Bedaquiline			Potential for increased risk of bedaquiline adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased bedaquiline levels	Avoid combination and use alternative agents. If coadministering, monitor liver function and QTc interval
6556	Darunavir Ranolazine 941	Darunavir			Ranolazine			Potential for increased risk of ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias)	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine and darunavir	Use alternative agents
6572	Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 957	Darunavir	800 mg with 100 mg ritonavir once daily	Cmax decrease 21%, AUC increase 34%, Cmin decrease 46%	Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir	250 mg BID + 25 / 150 / 100 mg once daily	Dasabuvir Cmax decrease 25%, AUC decrease 28%, Cmin decrease 35%; Ombitasvir Cmax, AUC, and Cmin decrease 13%; Paritaprevir Cmax decrease 30%, AUC decrease 19%, Cmin increase 59%	Potential decreased anti-HCV and anti-HIV efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of darunavir	Use alternative agents
6588	Darunavir Mometasone 973	Darunavir			Mometasone			Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents, particularly for long term use	Beclomethasone, prednisone, prednisolone
6604	Darunavir Prasugrel 989	Darunavir			Prasugrel			Potential for decreased antiplatelet activity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
6620	Darunavir Terazosin 1005	Darunavir			Terazosin			Potential for increased risk of terazosin adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate at lowest dose and titrate while monitoring for clinical response / adverse effects
6636	Darunavir Nefazodone 1021	Darunavir			Nefazodone			Potential for increased risk of nefazodone adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for adverse effects
6493	Darunavir Bosentan 878	Darunavir			Bosentan			Potential for increased risk of bosentan adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of bosentan	Start low and titrate bosentan to effect. If patient has been on protease inhibitor (other than unboosted atazanavir) for more than 10 days, start bosentan at 62.5 mg daily or every other day. If patient is currently on bosentan and requires a PI (other than unboosted atazanavir), stop bosentan for at least 36 hours prior to initiating ART. Wait 10 days and then resume bosentan starting with 62.5 mg daily or every other day.
6509	Darunavir Saxagliptin 894	Darunavir			Saxagliptin			Potential for increased saxagliptin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased saxagliptin levels	If coadministering, do not exceed saxagliptin dose of 2.5 mg once daily
6525	Darunavir NVP 910	Darunavir	400 mg with 100 mg ritonavir BID	Cmax increase 40%, AUC increase 24%, Cmin increase 2%	Nevirapine	200 mg BID	Cmax increase 18%, AUC increase 27%, Cmin increase 47%		Green: Administer standard doses	Administer standard doses
6541	Darunavir Dihydroergotamine 926	Darunavir			Dihydroergotamine			Potential for increased risk of dihydroergotamine adverse effects (e.g. peripheral vasospasm, ischemia)	Red: Avoid combination	Do not coadminister: Potential for increased dihydroergotamine levels	Contraindicated. Use alternative agents.	5-HT agonists ("triptans")
6557	Darunavir Silodosin 942	Darunavir			Silodosin			Potential for increased risk of silodosin adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of silodosin	Contraindicated. Use alternative agents.
6573	Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 958	Darunavir	800 mg daily	Darunavir Cmax decreased 8%; AUC decreased 24%; Cmin decreased 48%	Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir	250 mg BID + 25 / 150 / 100 mg once daily	Dasabuvir Cmax increase 10%, AUC decrease 6%, Cmin increase 10%; Ombitasvir Cmax and AUC decrease 14%, Cmin decrease 13%; Paritaprevir Cmin increase 54%, AUC increase 29%, Cmin increase 30%	Potential decreased anti-HCV and anti-HIV efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of darunavir	Use alternative agents
6589	Darunavir Triamcinolone 974	Darunavir			Triamcinolone			Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents, particularly for long term use	Beclomethasone, prednisone, prednisolone
6605	Darunavir Rivaroxaban 990	Darunavir			Rivaroxaban			Potential for increased bleeding risk	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents	Dabigatran
6621	Darunavir Buspirone 1006	Darunavir			Buspirone			Potential for increased risk of busprione adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate buspirone at low dose and titrate to effect
6637	Darunavir Ziprasidone 1022	Darunavir			Ziprasidone			Potential for increased risk of ziprasidone adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for adverse effects
6494	Darunavir Brexpiprazole 879	Darunavir			Brexpiprazole			Potential for increased risk of brexpiprazole adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of brexpiprazole	Administer 25% of the usual brexpiprazole dose. Titrate dose based on clinical monitoring for efficacy / adverse events.
6510	Darunavir Solifenacin 895	Darunavir			Solifenacin			Potential for increased risk of zolpidem adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased solifenacin levels	If coadministering, do not exceed solifenacin 5 mg once daily
6526	Darunavir TDF 911	Darunavir	300 mg with 100 mg ritonavir twice daily	Cmax increase 16%, AUC increase 21%, Cmin increase 24%	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increase 24%, AUC increase 22%, Cmin increase 37%		Green: Administer standard doses	Administer standard doses
6542	Darunavir Dronedarone 927	Darunavir			Dronedarone			Potential for increased risk of dronedarone adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased dronedarone levels	Use alternative agents
6558	Darunavir Simvastatin 943	Darunavir		Not studied	Simvastatin		Not studied (may increase simvastatin levels)	Increased risk of simvastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Contraindicated. Use alternative agents.	Atorvastatin (low dose)